{"address1": "777 Old Saw Mill River Road", "city": "Tarrytown", "state": "NY", "zip": "10591-6707", "country": "United States", "phone": "914 847 7000", "website": "https://www.regeneron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.", "fullTimeEmployees": 15158, "companyOfficers": [{"maxAge": 1, "name": "Dr. Leonard S. Schleifer M.D., Ph.D.", "age": 71, "title": "Co-Founder, President, CEO & Co-Chairman", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 6823034, "exercisedValue": 117275128, "unexercisedValue": 192379808}, {"maxAge": 1, "name": "Dr. George D. Yancopoulos M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 6796783, "exercisedValue": 95717904, "unexercisedValue": 188321072}, {"maxAge": 1, "name": "Mr. Christopher R. Fenimore CPA", "age": 53, "title": "Executive VP of Finance & CFO", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1269250, "exercisedValue": 9054700, "unexercisedValue": 16618295}, {"maxAge": 1, "name": "Dr. Andrew J. Murphy Ph.D.", "age": 65, "title": "Executive Vice President of Research", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1613560, "exercisedValue": 26279800, "unexercisedValue": 56244512}, {"maxAge": 1, "name": "Mr. Daniel P. Van Plew", "age": 51, "title": "Executive VP and GM of Industrial Operations & Product Supply", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 1905481, "exercisedValue": 20283170, "unexercisedValue": 9502018}, {"maxAge": 1, "name": "Ms. Patrice  Gilooly", "title": "Senior Vice President of Quality Assurance & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  McCowan", "title": "Senior VP of IT & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Crowe", "title": "Senior Vice President of Investor Relations & Strategic Analysis", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph J. LaRosa J.D.", "age": 65, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1748110, "exercisedValue": 23227300, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Lozner", "title": "Senior VP & Chief Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.regeneron.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 547.74, "open": 547.75, "dayLow": 546.61, "dayHigh": 551.56, "regularMarketPreviousClose": 547.74, "regularMarketOpen": 547.75, "regularMarketDayLow": 546.61, "regularMarketDayHigh": 551.56, "dividendRate": 3.52, "dividendYield": 0.67, "exDividendDate": 1747699200, "payoutRatio": 0.0224, "beta": 0.307, "trailingPE": 13.906504, "forwardPE": 12.080335, "volume": 456413, "regularMarketVolume": 456413, "averageVolume": 1351303, "averageVolume10days": 1100710, "averageDailyVolume10Day": 1100710, "bid": 504.34, "ask": 547.83, "bidSize": 2, "askSize": 1, "marketCap": 59095719936, "fiftyTwoWeekLow": 476.49, "fiftyTwoWeekHigh": 1211.2, "priceToSalesTrailing12Months": 4.195441, "fiftyDayAverage": 552.2456, "twoHundredDayAverage": 716.25446, "trailingAnnualDividendRate": 0.88, "trailingAnnualDividendYield": 0.0016066016, "currency": "USD", "tradeable": false, "enterpriseValue": 49829785600, "profitMargins": 0.31941998, "floatShares": 99889821, "sharesOutstanding": 106148000, "sharesShort": 2031432, "sharesShortPriorMonth": 2798186, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0188, "heldPercentInsiders": 0.018919999, "heldPercentInstitutions": 0.91986, "shortRatio": 1.35, "shortPercentOfFloat": 0.0198, "impliedSharesOutstanding": 107965000, "bookValue": 277.503, "priceToBook": 1.9724472, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "earningsQuarterlyGrowth": 0.12, "netIncomeToCommon": 4499299840, "trailingEps": 39.36, "forwardEps": 45.31, "enterpriseToRevenue": 3.538, "enterpriseToEbitda": 11.145, "52WeekChange": -0.47981942, "SandP52WeekChange": 0.12677538, "lastDividendValue": 0.88, "lastDividendDate": 1747699200, "quoteType": "EQUITY", "currentPrice": 547.36, "targetHighPrice": 940.0, "targetLowPrice": 504.0, "targetMeanPrice": 727.21375, "targetMedianPrice": 747.565, "recommendationMean": 1.84615, "recommendationKey": "buy", "numberOfAnalystOpinions": 24, "totalCash": 8349400064, "totalCashPerShare": 79.017, "ebitda": 4471000064, "totalDebt": 2704800000, "quickRatio": 3.9, "currentRatio": 4.927, "totalRevenue": 14085699584, "debtToEquity": 9.204, "revenuePerShare": 130.878, "returnOnAssets": 0.0691, "returnOnEquity": 0.15961, "grossProfits": 6873699840, "freeCashflow": 2082887552, "operatingCashflow": 3953100032, "earningsGrowth": 0.159, "revenueGrowth": -0.037, "grossMargins": 0.48799, "ebitdaMargins": 0.31741, "operatingMargins": 0.19943, "financialCurrency": "USD", "symbol": "REGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "CLOSED", "shortName": "Regeneron Pharmaceuticals, Inc.", "longName": "Regeneron Pharmaceuticals, Inc.", "corporateActions": [], "postMarketTime": 1751576271, "regularMarketTime": 1751562000, "exchange": "NMS", "messageBoardId": "finmb_33715", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.0693769, "regularMarketPrice": 547.36, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 670602600000, "postMarketChangePercent": 0.06394999, "postMarketPrice": 547.71, "postMarketChange": 0.35003662, "regularMarketChange": -0.380005, "regularMarketDayRange": "546.61 - 551.56", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1351303, "fiftyTwoWeekLowChange": 70.869995, "fiftyTwoWeekLowChangePercent": 0.14873344, "fiftyTwoWeekRange": "476.49 - 1211.2", "fiftyTwoWeekHighChange": -663.83997, "fiftyTwoWeekHighChangePercent": -0.54808456, "fiftyTwoWeekChangePercent": -47.98194, "dividendDate": 1749168000, "earningsTimestamp": 1754051400, "earningsTimestampStart": 1754051400, "earningsTimestampEnd": 1754051400, "earningsCallTimestampStart": 1754051400, "earningsCallTimestampEnd": 1754051400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 39.36, "epsForward": 45.31, "epsCurrentYear": 35.44704, "priceEpsCurrentYear": 15.4416275, "fiftyDayAverageChange": -4.88562, "fiftyDayAverageChangePercent": -0.008846825, "twoHundredDayAverageChange": -168.89447, "twoHundredDayAverageChangePercent": -0.23580234, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "displayName": "Regeneron Pharmaceuticals", "trailingPegRatio": 1.1714}